Zimmer acquires ETEX for its biologics portfolio
Zimmer Acquires ETEX Holdings, Inc. (press release)
Zimmer Expands Portfolio of Early Intervention and Joint Preservation Solutions
Zimmer Holdings, Inc. announced today that it has acquired the business of Cambridge, Massachusetts-based ETEX Holdings, Incorporated. The financial terms of the transaction were not disclosed. The acquisition enhances Zimmer’s Biologics portfolio of differentiated treatments through the addition of ETEX’s Beta-bsm™ (Injectable), CarriGen®, EquivaBone® (including DBM), andGamma-bsm™ (Putty) bone void filler products.
“Since 1989, ETEX has been focused on Dosuk Lee’s vision of providing clinical solutions that advance the orthopaedic standard of care. His breakthrough technology in biomimetic calcium phosphate, which mimics the chemical and structural features of human bone, promotes natural bone regeneration that positively impacts patients’ lives,” said Stephen R. La Neve, ETEX President and Chief Executive Officer. “Zimmer’s long history, dedication and focus in the orthopaedic market is a perfect complement to our technology and dramatically expands our ability to reach a broader array of clinicians.”
“Zimmer is committed to developing the most comprehensive range of biologic therapies for patients suffering from musculoskeletal joint disease, from early intervention solutions like Gel-One®* Cross-linked Hyaluronate and joint preservation solutions like Zimmer Knee Creations™ Subchondroplasty® Procedure, along with Zimmer’s Chondrofix® Osteochondral Allograft and Denovo® NT Natural Tissue Graft personalized cartilage solutions. ETEX’s innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease,” said Joseph A. Cucolo, President, Zimmer Americas.
*Gel-One is a registered trademark of Seikagaku Corporation.
About the Company
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products. Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries. Zimmer’s 2013 sales were approximately$4.6 billion. The Company is supported by the efforts of more than 9,000 employees worldwide. More information about Zimmer is available at www.zimmer.com.
About ETEX Holdings, Inc.
Established in 1989, ETEX Holdings, Inc. develops, manufactures and commercializes calcium phosphate-based biomaterials for improved orthopedic clinical outcomes. A leader in bioresorbable bone substitute materials, ETEX focuses on expanding applications through combinations with cells, biologics, or therapeutic agents delivered in minimally invasive and easy to use systems. For more information, visit www.etexcorp.com.
SOURCE Zimmer Holdings, Inc.